Questions? Chat with the founder on WhatsApp

Chat with the founder on WhatsApp
Arthneeti
HomeRankingsIPOScreenerInstitutions
HomeRankingsIPOScreenerInstitutions
Fabtech Technologies LtdQ1 FY27Healthcare Services
Home/Stocks/Fabtech Technologies Ltd/Q1 FY27

Fabtech Technologies Ltd Q1 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹148P/E: 13.8Market Cap: ₹673 CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • →Fabtech Technologies aims for 20-25% year-on-year organic growth.
  • →Target to achieve ₹1000 crore+ top-line by 2030, considered a conservative estimate.
  • →Q2 is expected to be steady, with stronger H2 performance typically seen in the EPC design and build industry.
  • →Active inquiries exceed ₹9300 crore with hot leads over ₹3800 crore, providing two-year sales visibility.
  • →Growth driven by deeper localization, pipeline conversion with disciplined order selection focusing on quality, and integration of acquisitions to boost local execution.
  • →Expansion into GCC, Eastern and Southern Africa markets, notably through Fabtech Life Care in Saudi Arabia.
  • →Large ticket opportunities delayed due to geopolitical factors, but no cancellations, with ongoing client engagement.
  • →Focus on profitable growth with disciplined execution and working capital efficiency.

Margin guidance

Category 2
  • →Fabtech Technologies targets 20-25% year-on-year organic growth going forward (Page 9, 18, 21).
  • →PAT guidance for current year is 9-11%, with aspirations toward 9.5-10% in the near term and 12% next year (Page 18).
  • →Company aims for gradual margin expansion driven by a combination of gross margin improvement and operating leverage (Page 21).
  • →Improvement in contribution margin was seen recently, expanding by ~900 basis points to 46.7% (Page 8).
  • →Long-term vision includes reaching a 1000+ crore revenue mark by 2030 through organic growth (Page 18).
  • →The business is seasonal with H2 typically stronger; growth in H2 is expected to be stronger than H1 (Page 9).
  • →Company is working on contracts to shift revenue recognition more towards percentage completion method, which may improve profitability visibility (Page 20).
  • →Profitability turnaround seen with net profit of Rs. 4.21 crores in Q1 FY27 from a loss last year (Page 8).

3 more insights locked — sign up free to unlock

Fundraise plans

  • →The document does not explicitly mention any current or planned new fundraising through debt or equity.
  • →Capital allocation is focused on execution and strategic acquisitions only after due diligence.
  • →Idle capital is currently held in fixed deposits (FT) awaiting suitable acquisition opportunities.
  • →There is emphasis on organic growth and deploying capital based on project requirements and order book growth.
  • →Management is concentrated on profitable, disciplined growth rather than raising new funds immediately.
  • →Acquisitions will be funded only when a strategic fit is confirmed through due diligence, indicating a cautious approach to fundraising.

Order book

Yes
  • →The current open order book is reported to be over ₹900 crores (approximately ₹920+ crores considering exchange rate fluctuations).
  • →During Q1 FY27, new order inflows of ₹96.5 crores were added, while around ₹75 crores of orders were delivered.
  • →Order book revenue recognition does not occur evenly across quarters; Q1 is typically the lightest in revenue due to milestone-based recognition.
  • →Active inquiries exceed ₹9,300 crores in the total addressable funnel.
  • →Hot leads, representing advanced commercial or technical opportunities with a path to conversion, are valued over ₹3,800 crores.
  • →Some large-ticket opportunities have slipped due to geopolitical conditions and funding cycles but with no cancellations.
  • →The company has a two-year visibility on its pipeline and is focused on quality order conversion over volume.

Capex plans

Yes
  • →Fabtech Technologies Limited has made strategic acquisitions to support growth:
  • → - Acquired majority stake in Specialized Activities Contracting Establishment (SACE) in Saudi Arabia for local presence and bidding on HVAC MEP and civil projects.
  • → - Ongoing due diligence for a European acquisition expected to drive future market entry, with completion anticipated within 2-3 quarters.
  • →Capital allocation focuses on execution, with working capital released only when order book growth and project requirements align.
  • →Acquisitions are strategically fit-driven, with capital deployment following due diligence and integration suitability.
  • →Investments post-IPO have been made in leadership and operational excellence.
  • →Technology investments include digital tools, 3D modeling, and AI integration to improve project delivery timelines.
  • →No specific high-value Greenfield CAPEX amount mentioned, but focus on profitable and disciplined growth with working capital efficiency.

How does Fabtech Technologies Ltd rank vs peers in Healthcare Services?

Pro feature
1Fabtech Technologies Ltd
Rev 2Mar 2
2Healthcare Services Company A
Rev 1Mar 2
3Healthcare Services Company B
Rev 2Mar 1
4Healthcare Services Company C
Rev 2Mar 3

See full Healthcare Services sector rankings

How does Fabtech Technologies Ltd rank in Healthcare Services?

Compare Fabtech Technologies Ltd against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Related research

Read the full Q1 FY27 earnings insight — Fabtech Technologies Ltd

Other quarters — Fabtech Technologies Ltd

Q4 FY26Q3 FY26Q2 FY26

Healthcare Services peers

Apollo Hospitals Enterprise Ltd · Q4 FY26Fortis Health. · Q1 FY27Syngene Intl. · Q4 FY26Dr Lal Pathlabs · Q1 FY27Narayana Hrudaya · Q1 FY27
Fabtech Technologies Ltd full stock analysisHealthcare Services sectorEarnings call directoryRankings dashboard

Questions about this analysis? Chat directly with the founder — real answers about the research, not a support bot.

WhatsApp the founder

Research team or advisory firm? Get earnings-call intelligence and ranking history as research inputs for your firm.

For Institutions

Arthneeti AI

AI-powered stock analysis from earnings call transcripts. Helping Indian investors make smarter decisions with data-driven insights.

Analysis

  • Stock Rankings
  • Sectors
  • Compare Stocks
  • IPO Dashboard
  • Stock Screener
  • Earnings Call Analysis
  • Stocks Under ₹500
  • Multibaggers

Tools

  • MF Overlap Checker
  • SIP Calculator
  • CAGR Calculator
  • FD vs Equity
  • All Calculators

Resources

  • Blog
  • Weekly Digest
  • Portfolio Analysis
  • Build Portfolio
  • Earnings Calendar
  • Q1 FY27 Earnings Hub

Company

  • Pricing
  • How Our Analysis Works
  • For Institutions
  • Terms of Service
  • Privacy Policy

Compare

  • vs Screener.in
  • vs Trendlyne
  • vs Tickertape
  • vs Moneycontrol Pro
+91 90841 32575 support@arthneeti.com Bengaluru, India

© 2026 Arthneeti AI. All rights reserved.

AI-analyzed data from 1,500+ company earnings calls

Continue your research

What Fabtech Technologies Ltd's management said in earlier quarters

  • Q1 FY27 earnings call analysis →
  • Q4 FY26 earnings call analysis →
  • Q3 FY26 earnings call analysis →

Others in Healthcare Services this season

  • Rainbow Childrens Medicare Ltd (Q1 FY27)

    Volume growth supported by planned addition of 2,500 beds over 5 years (~15% CAGR) (Page 10). Key concall takeaways from Rainbow Childrens Medicare Ltd's Q1…

  • Dr Lal Pathlabs (Q1 FY27)

    140 crore to Rs. Key concall takeaways from Dr Lal Pathlabs's Q1 FY27 earnings call — and how it ranks against sector peers.

  • Vimta Labs Ltd (Q1 FY27)

    The company's various business units are growing at almost double the industry's CAGR (8%-11%). Key concall takeaways from Vimta Labs Ltd's Q1 FY27 earnings…

  • Dr Agarwal's Hea (Q1 FY27)

    Q1 FY27 revenue from operations grew 26% year-on-year to INR614 crores, driven by both volume and value growth (~16% each). Key concall takeaways from Dr…

Compare:vs Apollo Hospitals Enterprise Ltdvs Max Healthcarevs Fortis Health.